Everything You Need To Know To Find The Best Sorbitol Crystal20-30 Mesh

A kind of erlotinib Hydrochloride composition tablet and preparation method thereof Technical field The invention belongs to pharmaceutical preparations technology field, be specifically related to a kind of erlotinib Hydrochloride composition tablet and preparation method thereof. Background technology Since nearly half a century, the incidence of disease of lung cancer and the death rate are all increasing year by year, and 20 beginning of the century lung cancer still compare the most rare disease, to 20 the end of the century lung cancer accounted for the first place of mortality of malignant tumors.Show according to the data that the World Health Organization (WHO) periodically announces, the M & M of lung cancer in countries in the world all in obvious ascendant trend, especially industry prosperityCountry.The whole world has more than 200 ten thousand to increase patients with lung cancer newly every year, and dead more than 100 ten thousand；China increases patients with lung cancer more than 50 ten thousand every year newly, and dead more than 30 ten thousand.Lung cancer has replaced liver cancer to become China's first place Death Cause for Malignant Tumors at present, accounts for the 22.7% of whole mortality of malignant tumors, and M & M is still continuing rising rapidly. Lung cancer is referred to as " soundless killer ", in early days, falls ill and is difficult to find mid-term, and once finding just to reach an advanced stage, all of medical procedure is all without positive effect.In the U.S., lung cancer is the cancer causing value of life loss the highest, and lung cancer is that in all cancers, financial burden is fastest-rising.Lung cancer mortality adds nearly 1.5 times between 20 years of 20 century 70 mid-term to the initial stages nineties, is that in all malignant tumours, increasing degree is the highest.Estimated 222,500 examples of the morbidity example (male sex 116,750 examples, and women 105,770 examples) of U.S.'s lung cancer in and bronchiolar carcinoma, dead 157,300 examples (male sex 86,200 examples, and women 71,100 examples). Clinical Oncology cooperation center of Chinese Anti-Cancer Association designates General Board, Guangdong People's Hospital professor Wu Yilong points out, show according to the statistics about China's tumor incidences in and the death rate of issue in , the incidence of disease of overall crowd's lung cancer is 53.57/10 ten thousand, and the death rate is 45.57/10 ten thousand.Wherein the lung cancer morbidity rate of the male sex is 70.4/10 ten thousand, and the death rate is 61.0/10 ten thousand, and M & M divides row male tumor the first；The lung cancer morbidity rate of women is 36.34/10 ten thousand, and the death rate is 29.77/10 ten thousand, and M & M divides row female tumor second and first.The lung cancer patient that China increases newly every year about 500,000, adds original the people that cures the disease, every year at the patient's number controlled at least more than 600,000.Data from the 6th lung cancer in China north and south summit forum (in November, , Beijing was held) show, China's lung cancer morbidity rate increases by 26.9% every year at present, as taked effective control measure not in time, expect , China's lung cancer patient is up to 1,000,000, becomes the first in the world lung cancer big country. Lung cancer is a process multifactor, multistage, smoking, be exposed to ETS, Indoor Air Pollution with outdoor Air Pollution, eating habit, drink, breathing problem history, Family history of cancer etc. the most relevant with lung cancer. Lung cancer receives much concern as the malignant tumour that the global range incidence of disease and case fatality rate are the highest always.Nearly ten years, along with smoking cessation and the change of habits and customs, the incidence of disease of male lung cancer progressivelyes reach platform, even start that downward trend occurs, but rapid increase occurs in the incidence of disease of female lung cancer, its onset peak predicts present the year two thousand twenty, and this growth trend is referred to as one " epoch popular ". In the sixties in last century five, chemotherapeutic occurs." mistake would rather kill 3,000, it is impossible to let slip one ", chemotherapeutic is while killing tumour cell, and benign cell is also killed in a large number, and side effect is very big.Many patients are not to die from cancer, but die from chemotherapy. From last century Mo to the beginning of this century, massive tumor Celluar and Molecular Biology result of study shows, tumor cell surface exists some specific gene expression of receptor.This provides new thinking for development targeting anticarcinogen affects the active procedure of tumour cell by interference or blocking-up receptor protein expression approach, reaches therapeutic purposes.Under this strategy instruction, research and development have listed a series of small molecular protein tyrosine kinase inhibitor. Many studies demonstrate that the clinical efficacy of the Anti-angiogenesis preparation being applied to VEGF (VEGF) family and acceptor, these results of study promote the development of VEGF inhibitor.Since the nineties in 20th century, targeted therapy enters the people visual field gradually, and EGF-R ELISA (epidermal growth factorreceptor, EGFR) is the tyrosine kinase receptor of a kind of cross-film, high expressed in NSCLC.Tyrosine kinase inhibitor (TKI) brings new selection to advanced NSCLC treatment. In 10 years in past, along with the progress of preclinical medicine, the discovery of some new antineoplastic target spots, the medicament research and development of tumor area there occurs great variety, the molecular targeted agents having turned to non-cytotoxicity class from traditional cytotoxic drug is developed, and has successivelyNew productProduct list.The clinical practice of molecular targeted agents changes the result for the treatment of of part lung cancer, is that anti-lung-cancer medicament treats the field attracted most attention so far.But, any one molecular targeted agents of listing is only effective to fraction crowd at present, and most tumors patient fails to benefit. At present, if antineoplastic target drug main monoclonal antibody drug, small-molecule drug and apoptosis-inducing medicine.Although antineoplastic target medicine is as common antineoplastic, face the pressure of Patent expiry equally, but, antineoplastic meets far away the market demand of differentiation treatment, thus becomes the important impetus can not despised in drug market.Along with domestic and international medication market gradually integrate with andNationalThe raising of Medical Consumption level, targeting anti-tumor medicine sample hospital market at home also shows the situation of strong growth.Anti-tumor small molecular targeted drug has the advantages that action target spot is clear and definite, curative effect is preferable, side effect is relatively low, life cycle and life quality for having the cancer patient of gene mutation during treatment all have the biggest effect, the future trend having become clinical application and the kind got most of the attention.And, WHO has occurred that change for the definition of tumour, i.e. tumour is a kind of long-term chronic disease.This makes the oncotherapy in future there occurs earth-shaking change.Therefore, it is possible to the molecular targeted agents making patient be greatly improved life quality is just accepted by the most vast patient. Tarceva (Erlotinib) is a kind of small molecule anticancer drug that Genentech, Roche and Osi Pharm Inc. develop jointly.In November, and in September, are examined, in seven, 80, the whole world by U.S. FDA and Europe EMEA respectivelyCountryListing.This medicine is a kind of oral small molecule EGFR tyrosine inhibitors of kinases.II clinical trial phase result report, Tarceva single therapy advanced NSCLC remission rate is 10%-30%.III clinical trial phase of one large sample, those selected is the advanced NSCLC patients that platinum containing regimens chemotherapy is failed, Tarceva compares with placebo, and get nowhere phase, middle position disease-free period of median survival interval, 1 year survival rate, remission rate, middle position is superior to comfort unit (p ∠ 0.001).According to U.S. Montefiore medical center introduction, Tarceva has the advantages that oral dose is little, drug plasma exposure concentrations high and the half-life is short, and every day, repeat administration was not result in drug accumulation. Erlotinib Hydrochloride is atomic is dissolved in water, is slightly soluble in methyl alcohol, is practically insoluble in acetonitrile, acetone, ethyl acetate and n-hexane.By Biopharmaceutics Classification standard, erlotinib Hydrochloride belongs to II class, i.e. Thief zone, low lysotype medicine, and the In Vitro Dissolution of medicine is the key factor affecting preparation bioavilability, therefore increases drug solubility, to improve drug-eluting particularly important.It addition, erlotinib Hydrochloride less stable, especially to wet, heat endurance is poor, and the tablet using wet granulation technology to prepare is difficult to be disintegrated, and therefore frequently with by drug micronization in prior art, then carries out the preparation of tablet by the technique of dry granulation.But, it is prone to after drug micronization reassemble, affects mixing uniformity；Increase production cost；Dust is relatively big, and is severe toxicity medicine, is unfavorable for labour protection.Dry granulation process is inefficient, and the particle of preparation is uneven, and mobility of particle is poor, and material can reduce the dissolution of medicine after twice compacting further. CNA discloses a kind of erlotinib Hydrochloride Pharmaceutical composition and preparation method thereof, bulk drug is formed solid dispersions with decentralized medium polyethylene glycol, it is equipped with filler, disintegrant and lubricant again, uses the granulation of pharmaceutically acceptable preparation method, compressing tablet or load capsule.This invention improves the dissolution rate of medicine to a certain extent, but owing to preparation specification is relatively big, the tablet prepared after preparing solid dispersions is relatively big, is not easy to take；Use fusion method to prepare solid dispersions and have impact on the stability of preparation；Polyethylene glycol fusing point is relatively low, easily occurs sticking phenomenon in tableting processes；Polyethylene glycol water content is higher, causes having related substance to increase in preparation storing process very fast. CNA discloses a kind of erlotinib Hydrochloride sheet, containing accounting for prescription gross weight 2～the silica of 12%, can promote dissolution.But using silica in a large number, preparation is prone to moisture absorption, the stability of impact. Summary of the invention It is an object of the invention to solve at least the above and/or defect, and the advantage that at least will be described later is provided. In order to realize according to object of the present invention and further advantage, providing a kind of erlotinib Hydrochloride composition tablet, the composition of described tablet includes by weight percentage: erlotinib Hydrochloride crystal 20～38%, pre-paying starch 30～50%, calcium sulfate 25～45%, ethyl cellulose 1～5%, beta-schardinger dextrin 6～12%, tween 0.2～3%, crosslinked carboxymethyl fecula sodium 5～10%, sodium stearyl fumarate 0.5～1.5%, superfine silica gel powder 0.2～2%. Preferably, the composition of described tablet includes by weight percentage: erlotinib Hydrochloride crystal 25%, pre-paying starch 30%, calcium sulfate 25%, ethyl cellulose 2%, beta-schardinger dextrin 10%, tween 0.5%, crosslinked carboxymethyl fecula sodium 5%, sodium stearyl fumarate 1.5%, superfine silica gel powder 1%. Preferably, described ethyl cellulose is substituted by konjaku glucomannan；Described crosslinked carboxymethyl fecula sodium is substituted by sodium carboxymethylcellulose or Ac-Di-Sol. The preparation method of a kind of above-mentioned erlotinib Hydrochloride composition tablet, comprises the following steps: Step one, by erlotinib Hydrochloride crystal with pre-paying starch, calcium sulfate, crosslinked carboxymethyl fecula sodium under the rotating speed of 300～500r/min, mix, pulverize, cross 100～200 mesh screen cloth, obtain the compound particles of 100～200 mesh； Step 2, ethyl cellulose, beta-schardinger dextrin, tween are added volume ratio is in the purified water of 1:2～4 and ethanol, it is uniformly mixing to obtain granulation liquid, granulation liquid is added in compound particles, stir, filter, pelletize, obtain wet granular, wet granular is dried to obtain at 60～80 DEG C dry particle, controls dry particle free moisture≤1.2%；Described dry particle is crossed the screen cloth of 40～60 mesh, obtains the 40～60 dry particles of purpose；Described ethyl cellulose and volume ratio are the purified water of 1:2～4 and the weight ratio of ethanol is 1:2～4； Step 3, in the described 40～60 dry particles of purpose, add sodium stearyl fumarate and superfine silica gel powder, stir, obtain mixture； Step 4, mixture step 3 obtained are dried so that it is middle moisture≤1.2%, then carry out compressing tablet, and are coated described compressing tablet, obtain erlotinib Hydrochloride composition tablet. Preferably, the mode that described granulation liquid adds in compound particles is: be input to be applied with by granulation liquid in the stainless steel shower nozzle of voltage, stainless steel shower nozzle applies high-pressure electrostatic by high voltage power supply, granulation liquid is sprayed from stainless steel shower nozzle and is ejected into the reception device of the compound particles filled, wherein, in course of injection, hybrid particles is stirred by the agitator that reception dress centers；The internal diameter that the output voltage of high voltage power supply is 8～15kv, reception device is 10～15cm with the spacing of stainless steel shower nozzle jet, the flow velocity of granulation liquid is 5～10mL/h stainless steel shower nozzles is 0.5～1.2mm. Preferably, the hardness of described compressing tablet is at 5-8kgf. Preferably, described coating makes described compressing tablet weightening finish 2-4wt%；The aqueous solution of the Opadry II that coating solution is 15wt% that described coating uses. Preferably, the preparation method of described erlotinib Hydrochloride crystal is: join in dimethyl sulphoxide solution by erlotinib Hydrochloride crude product and polymethyl methacrylate that weight ratio is 1:4～6, add thermal agitation to being completely dissolved, obtain mixture solution, it is input to mixture solution be applied with in the stainless steel shower nozzle of voltage, stainless steel shower nozzle applies high-pressure electrostatic by high voltage power supply, mixture solution is sprayed from stainless steel shower nozzle and is ejected into the reception device of the first alcohol and water that volume ratio is 1:1～3 filling 50～60 DEG C, after having sprayed, stir 2～4 hours, filter, it is 25KHz by filtrate in frequency, power output is under the sound field of 40W, it is cooled to-5～5 DEG C with 5～10 DEG C/h, growing the grain 3 hours, washing, vacuum drying, obtain erlotinib Hydrochloride crystal；Wherein, in course of injection, first alcohol and water is stirred by the agitator that reception dress centers；After injection completes, applying ultrasonic during stirring, described ultrasonic power regulating range is 800～W, and supersonic frequency is 25～50KHz；The environment temperature of course of injection is 50～60 DEG C, the output voltage of high voltage power supply is 3～8kv, reception device is 10～15cm with the spacing of stainless steel shower nozzle jet, the flow velocity of mixture solution is 2～5mL/h, the internal diameter of stainless steel shower nozzle is 0.8～1.2mm. Preferably, described dimethyl sulfoxide (DMSO) is 5～10:1 with the weight ratio of erlotinib Hydrochloride crude product. Preferably, the described mixing speed receiving the agitator that dress centers is 300～500r/min. The present invention at least includes following beneficial effect: (1) the preparation technology route of erlotinib Hydrochloride composition tablet of the present invention is stable, the most easily operated, the technological parameter of setting can effectively control the reaction of each step, sample survey result display erlotinib Hydrochloride bulk drug stable crystal form, purity is preferable, can meet the quality requirement of finished product.Proterties, discriminating, Related substances separation and the assay etc. of erlotinib Hydrochloride of the present invention are carried out system test, finally determines each corresponding quality standard and corresponding quality index.The stability of erlotinib Hydrochloride of the present invention is investigated, place 6 months under acceleration environment, place 12 months under the conditions of long term test, the appearance character of three batch samples, loss on drying, have related substance, content essentially unchangedization, it is ensured that the quality of medicine during Clinical practice.This product synthesis and production process is succinct, stable, feasible, it is adaptable to produce in enormous quantities；Quality controllable, stability is preferable. (2) erlotinib Hydrochloride crude product is processed by the present invention by high pressure electroblowing process, and by the precise controlling of crystallization condition, prepare a kind of erlotinib Hydrochloride crystal, this erlotinib Hydrochloride Crystal impurity content is low and good stability, preparation for preparation brings conveniently, and tablet dissolution rate compared with the prior art prepared by this erlotinib Hydrochloride crystalline compounds is high, good stability, moisture and impurity content are low, improve the security of clinical practice. Part is embodied by the further advantage of the present invention, target and feature by description below, and part is also by by being understood by the person skilled in the art the research of the present invention and practice. Accompanying drawing illustrates: Figure 1For the chlorination flow process in the preparation process of main ingredient erlotinib Hydrochloride of the present invention； Figure 2For the condensation reaction in the preparation process of main ingredient erlotinib Hydrochloride of the present invention； Figure 3For the flow process being refining to obtain erlotinib Hydrochloride finished product in the preparation of main ingredient erlotinib Hydrochloride of the present invention； Detailed description of the invention: Below in conjunction withAccompanying drawingThe present invention is described in further detail, to make those skilled in the art can implement according to this with reference to specification word. Should be appreciated that used herein such as " have ", other element one or more or the existence of a combination thereof or interpolation do not allotted in " comprising " and " including " term. Embodiment 1: A kind of erlotinib Hydrochloride composition tablet, the composition of described tablet includes by weight percentage: erlotinib Hydrochloride crystal 25%, pre-paying starch 30%, calcium sulfate 25%, ethyl cellulose 1%, beta-schardinger dextrin 10%, tween 2%, crosslinked carboxymethyl fecula sodium 5%, sodium stearyl fumarate 0.7%, superfine silica gel powder 1.3%. The preparation method of a kind of above-mentioned erlotinib Hydrochloride composition tablet, comprises the following steps: Step one, by erlotinib Hydrochloride crystal with pre-paying starch, calcium sulfate, crosslinked carboxymethyl fecula sodium under the rotating speed of 500r/min, mix, pulverize, cross 100 mesh screen cloth, obtain the compound particles of 100 mesh； Step 2, ethyl cellulose, beta-schardinger dextrin, tween are added volume ratio is in the purified water of 1:2 and ethanol, it is uniformly mixing to obtain granulation liquid, granulation liquid is added in compound particles, stir, filter, pelletize, obtain wet granular, wet granular is dried to obtain at 80 DEG C dry particle, controls dry particle free moisture≤1.2%；Described dry particle is crossed the screen cloth of 40 mesh, obtains the 40 dry particles of purpose；Described ethyl cellulose and volume ratio are the purified water of 1:2 and the weight ratio of ethanol is 1:2； Step 3, in the described 40 dry particles of purpose, add sodium stearyl fumarate and superfine silica gel powder, stir, obtain mixture； Step 4, mixture step 3 obtained are dried so that it is middle moisture≤1.2%, then carry out compressing tablet, and are coated described compressing tablet, obtain erlotinib Hydrochloride composition tablet；The hardness of described compressing tablet is at 5kgf；Described coating makes described compressing tablet weightening finish 2wt%；The aqueous solution of the Opadry II that coating solution is 15wt% that described coating uses. Embodiment 2: A kind of erlotinib Hydrochloride composition tablet, the composition of described tablet includes by weight percentage: erlotinib Hydrochloride crystal 25%, pre-paying starch 30%, calcium sulfate 25%, ethyl cellulose 2%, beta-schardinger dextrin 10%, tween 0.5%, crosslinked carboxymethyl fecula sodium 5%, sodium stearyl fumarate 1.5%, superfine silica gel powder 1%. The preparation method of a kind of above-mentioned erlotinib Hydrochloride composition tablet, comprises the following steps: Step one, by erlotinib Hydrochloride crystal with pre-paying starch, calcium sulfate, crosslinked carboxymethyl fecula sodium under the rotating speed of 300r/min, mix, pulverize, cross 200 mesh screen cloth, obtain the compound particles of 200 mesh； Step 2, ethyl cellulose, beta-schardinger dextrin, tween are added volume ratio is in the purified water of 1:4 and ethanol, it is uniformly mixing to obtain granulation liquid, it is input to granulation liquid be applied with in the stainless steel shower nozzle of voltage, stainless steel shower nozzle applies high-pressure electrostatic by high voltage power supply, granulation liquid is sprayed from stainless steel shower nozzle and is ejected into the reception device of the compound particles filled, stir, filter, pelletize, obtain wet granular, wet granular is dried to obtain at 60 DEG C dry particle, controls dry particle free moisture≤1.2%；Described dry particle is crossed the screen cloth of 60 mesh, obtains the 60 dry particles of purpose；Described ethyl cellulose and volume ratio are the purified water of 1:4 and the weight ratio of ethanol is 1:3；Wherein, in course of injection, hybrid particles is stirred by the agitator that reception dress centers；The internal diameter that the output voltage of high voltage power supply is 10kv, reception device is 10cm with the spacing of stainless steel shower nozzle jet, the flow velocity of granulation liquid is 5mL/h stainless steel shower nozzle is 0.5mm； Step 3, in the described 60 dry particles of purpose, add sodium stearyl fumarate and superfine silica gel powder, stir, obtain mixture； Step 4, mixture step 3 obtained are dried so that it is middle moisture≤1.2%, then carry out compressing tablet, and are coated described compressing tablet, obtain erlotinib Hydrochloride composition tablet；The hardness of described compressing tablet is at 7kgf；Described coating makes described compressing tablet weightening finish 3wt%；The aqueous solution of the Opadry II that coating solution is 15wt% that described coating uses. Embodiment 3: A kind of erlotinib Hydrochloride composition tablet, the composition of described tablet includes by weight percentage: erlotinib Hydrochloride crystal 30%, pre-paying starch 30%, calcium sulfate 25%, ethyl cellulose 1%, beta-schardinger dextrin 6%, tween 1%, crosslinked carboxymethyl fecula sodium 5%, sodium stearyl fumarate 0.7%, superfine silica gel powder 1.3%. The preparation method of a kind of above-mentioned erlotinib Hydrochloride composition tablet, comprises the following steps: Step one, erlotinib Hydrochloride crude product and polymethyl methacrylate that weight ratio is 1:4 are joined in dimethyl sulphoxide solution, add thermal agitation to being completely dissolved, obtain mixture solution, it is input to mixture solution be applied with in the stainless steel shower nozzle of voltage, stainless steel shower nozzle applies high-pressure electrostatic by high voltage power supply, mixture solution is sprayed from stainless steel shower nozzle and is ejected into the reception device of the first alcohol and water that volume ratio is 1:1 filling 50 DEG C, after having sprayed, stir 2 hours, filter, it is 25KHz by filtrate in frequency, power output is under the sound field of 40W, it is cooled to-5 DEG C with 5 DEG C/h, growing the grain 3 hours, washing, vacuum drying, obtain erlotinib Hydrochloride crystal；Wherein, in course of injection, first alcohol and water is stirred by the agitator that reception dress centers with 500r/min；After injection completes, applying ultrasonic during stirring, described ultrasonic power regulating range is at 800W, and supersonic frequency is at 25KHz；The environment temperature of course of injection is 60 DEG C, the output voltage of high voltage power supply is 3kv, receive device with the spacing of stainless steel shower nozzle jet be 15cm, the flow velocity of mixture solution be 5mL/h, the internal diameter of stainless steel shower nozzle be 1.2mm； Step 2, by erlotinib Hydrochloride crystal with pre-paying starch, calcium sulfate, crosslinked carboxymethyl fecula sodium under the rotating speed of 500r/min, mix, pulverize, cross 200 mesh screen cloth, obtain the compound particles of 200 mesh； Step 3, ethyl cellulose, beta-schardinger dextrin, tween are added volume ratio is in the purified water of 1:3 and ethanol, it is uniformly mixing to obtain granulation liquid, granulation liquid is added in compound particles, stir, filter, pelletize, obtain wet granular, wet granular is dried to obtain at 70 DEG C dry particle, controls dry particle free moisture≤1.2%；Described dry particle is crossed the screen cloth of 50 mesh, obtains the 50 dry particles of purpose；Described ethyl cellulose and volume ratio are the purified water of 1:3 and the weight ratio of ethanol is 1:3； Step 4, in the described 50 dry particles of purpose, add sodium stearyl fumarate and superfine silica gel powder, stir, obtain mixture； Step 5, mixture step 3 obtained are dried so that it is middle moisture≤1.2%, then carry out compressing tablet, and are coated described compressing tablet, obtain erlotinib Hydrochloride composition tablet；The hardness of described compressing tablet is at 8kgf；Described coating makes described compressing tablet weightening finish 3wt%；The aqueous solution of the Opadry II that coating solution is 15wt% that described coating uses. Embodiment 4: A kind of erlotinib Hydrochloride composition tablet, the composition of described tablet includes by weight percentage: erlotinib Hydrochloride crystal 20%, pre-paying starch 37%, calcium sulfate 25%, ethyl cellulose 2%, beta-schardinger dextrin 7%, tween 1%, crosslinked carboxymethyl fecula sodium 6%, sodium stearyl fumarate 0.5%, superfine silica gel powder 1.5%. The preparation method of a kind of above-mentioned erlotinib Hydrochloride composition tablet, comprises the following steps: Step one, erlotinib Hydrochloride crude product and polymethyl methacrylate that weight ratio is 1:5 are joined in dimethyl sulphoxide solution, add thermal agitation to being completely dissolved, obtain mixture solution, it is input to mixture solution be applied with in the stainless steel shower nozzle of voltage, stainless steel shower nozzle applies high-pressure electrostatic by high voltage power supply, mixture solution is sprayed from stainless steel shower nozzle and is ejected into the reception device of the first alcohol and water that volume ratio is 1:1 filling 50 DEG C, after having sprayed, stir 2 hours, filter, it is 25KHz by filtrate in frequency, power output is under the sound field of 40W, it is cooled to-5 DEG C with 5 DEG C/h, growing the grain 3 hours, washing, vacuum drying, obtain erlotinib Hydrochloride crystal；Wherein, in course of injection, first alcohol and water is stirred by the agitator that reception dress centers with 500r/min；After injection completes, applying ultrasonic during stirring, described ultrasonic power regulating range is at 800W, and supersonic frequency is at 25KHz；The environment temperature of course of injection is 60 DEG C, the output voltage of high voltage power supply is 3kv, receive device with the spacing of stainless steel shower nozzle jet be 15cm, the flow velocity of mixture solution be 5mL/h, the internal diameter of stainless steel shower nozzle be 1.2mm； Step 2, by erlotinib Hydrochloride crystal with pre-paying starch, calcium sulfate, crosslinked carboxymethyl fecula sodium under the rotating speed of 500r/min, mix, pulverize, cross 200 mesh screen cloth, obtain the compound particles of 200 mesh； Step 3, ethyl cellulose, beta-schardinger dextrin, tween are added volume ratio is in the purified water of 1:3 and ethanol, it is uniformly mixing to obtain granulation liquid, it is input to granulation liquid be applied with in the stainless steel shower nozzle of voltage, stainless steel shower nozzle applies high-pressure electrostatic by high voltage power supply, granulation liquid is sprayed from stainless steel shower nozzle and is ejected into the reception device of the compound particles filled, stir, filter, pelletize, obtain wet granular, wet granular is dried to obtain at 60 DEG C dry particle, controls dry particle free moisture≤1.2%；Described dry particle is crossed the screen cloth of 60 mesh, obtains the 60 dry particles of purpose；Described ethyl cellulose and volume ratio are the purified water of 1:3 and the weight ratio of ethanol is 1:3；Wherein, in course of injection, hybrid particles is stirred by the agitator that reception dress centers；The internal diameter that the output voltage of high voltage power supply is 10kv, reception device is 10cm with the spacing of stainless steel shower nozzle jet, the flow velocity of granulation liquid is 5mL/h stainless steel shower nozzle is 0.5mm； Step 4, in the described 50 dry particles of purpose, add sodium stearyl fumarate and superfine silica gel powder, stir, obtain mixture； Step 5, mixture step 3 obtained are dried so that it is middle moisture≤1.2%, then carry out compressing tablet, and are coated described compressing tablet, obtain erlotinib Hydrochloride composition tablet；The hardness of described compressing tablet is at 8kgf；Described coating makes described compressing tablet weightening finish 3wt%；The aqueous solution of the Opadry II that coating solution is 15wt% that described coating uses. Embodiment 5: A kind of erlotinib Hydrochloride composition tablet, the composition of described tablet includes by weight percentage: erlotinib Hydrochloride crystal 25%, pre-paying starch 30%, calcium sulfate 25%, konjaku glucomannan 1%, beta-schardinger dextrin 10%, tween 2%, sodium carboxymethylcellulose 5%, sodium stearyl fumarate 0.7%, superfine silica gel powder 1.3%. The preparation method of a kind of above-mentioned erlotinib Hydrochloride composition tablet, comprises the following steps: Step one, by erlotinib Hydrochloride crystal with pre-paying starch, calcium sulfate, sodium carboxymethylcellulose under the rotating speed of 500r/min, mix, pulverize, cross 100 mesh screen cloth, obtain the compound particles of 100 mesh； Step 2, konjaku glucomannan, beta-schardinger dextrin, tween are added volume ratio is in the purified water of 1:2 and ethanol, it is uniformly mixing to obtain granulation liquid, granulation liquid is added in compound particles, stir, filter, pelletize, obtain wet granular, wet granular is dried to obtain at 80 DEG C dry particle, controls dry particle free moisture≤1.2%；Described dry particle is crossed the screen cloth of 40 mesh, obtains the 40 dry particles of purpose；Described konjaku glucomannan and volume ratio are the purified water of 1:2 and the weight ratio of ethanol is 1:2； Step 3, in the described 40 dry particles of purpose, add sodium stearyl fumarate and superfine silica gel powder, stir, obtain mixture； Step 4, mixture step 3 obtained are dried so that it is middle moisture≤1.2%, then carry out compressing tablet, and are coated described compressing tablet, obtain erlotinib Hydrochloride composition tablet；The hardness of described compressing tablet is at 5kgf；Described coating makes described compressing tablet weightening finish 2wt%；The aqueous solution of the Opadry II that coating solution is 15wt% that described coating uses. Embodiment 6:

Document Informationclick to expand document information

This document provides standard veterinary treatment guidelines for veterinary clinics in Ethiopia. It discusses diseases of cattle, small ruminants like sheep and goats, and includes sections on non-infectious diseases, infectious diseases, diseases of the respiratory system, diseases of the reproductive system, and ectoparasites.

Check now

For more information, please visit TUBANG.

Want more information on Sorbitol Crystal20-30 Mesh? Feel free to contact us.